dr. david gandara on patient selection for molecular testing in lung cancer
Published 12 years ago • 129 plays • Length 1:34Download video MP4
Download video MP3
Similar videos
-
2:03
dr. david gandara discusses multiplexing molecular tests for nsclc
-
1:20
dr. david gandara describes exciting new lung cancer research
-
1:36
dr. david gandara on thymidylate synthase expression in alk-positive non-small cell lung cancer
-
5:40
concurrent versus sequential testing in nsclc
-
2:15
dr. gandara on practice-changing studies in lung cancer
-
1:02
dr. gandara on the mystic trial for lung cancer
-
0:53
dr. gandara on measuring tmb in nsclc
-
1:49
immunotherapy and beyond for lung cancer prevention
-
1:02
david gandara, md, current thinking regarding testing for pd-l1 biomarker in nsclc patients
-
2:22
dr. gandara on how lung-map trial is optimal for patient care
-
3:10
dr gandara: the role of the multidisciplinary team in molecular testing
-
3:30
the cost-effectiveness of targeted therapies in nsclc
-
5:58
common mutations in lung cancer
-
0:58
dr. david gandara spotlights the giants of cancer care
-
1:06
dr. gandara on recent advancements in field of lung cancer
-
2:53
dr gandara: perspective on tissue acquisition in mnsclc
-
2:07
dr. gandara on online treatment decision tool for lung cancer
-
0:58
david gandara, md,, discusses pd-l1 expression and selecting the appropriate agent in nsclc patients
-
1:40
dr. gandara discusses the oak trial for lung cancer